Clinical features and incidence rate of ocular complications in punctate inner choroidopathy

Theresa G. Leung, Ahmadreza Moradi, Dianna Liu, Quan D. Nguyen, James P. Dunn, Bryn Burkholder, Nicholas J. Butler, Trucian Ostheimer, Jennifer E. Thorne

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

PURPOSE: To study the clinical features and incidence rate of ocular complications in patients with punctate inner choroidopathy. METHODS: This is a retrospective cohort study conducted in a single-center academic practice setting. Patients diagnosed with punctate inner choroidopathy at the Wilmer Eye Institute, Johns Hopkins University from 1984 to 2012 were identified. Demographics and clinical features including the presence of choroidal neovascularization (CNV) and structural complications were collected. Main outcome measures, including visual impairment and incidence rate of ocular complications, were analyzed. RESULTS: Thirty-one patients (59 eyes) were included in the study. Follow-up data were available for 24 patients (47 eyes) with a mean follow-up time of 3.4 years (range, 2 months to 8.7 years). In the affected eyes with follow-up, the incidence rate of visual impairment to 20/50 or worse was 0.06 per eye-year (EY) (95% confidence interval, 0.022/EY-0.114/EY). The incidence rate of visual loss to 20/200 or worse was 0.006/EY (95% confidence interval, 0.0001/EY-0.034/EY). Thirty-six eyes (77%) had an ultimate visual acuity of 20/40 or better. All of the 13 patients with more than ≥3 years of follow-up had a visual acuity of ≥20/40 in at least 1 eye at 3 years after presentation. Two thirds of the follow-up patients (67%) on immunomodulatory drug therapy did not have new or recurrent CNV. However, this was not a statistically significant difference. Three eyes with follow-up had recurrence of CNV for an incidence rate of 0.04/EY (95% confidence interval, 0.008/EY-0.12/EY). Two eyes developed new CNV during follow-up for an incidence rate of 0.02/EY (95% confidence interval, 0.002/EY-0.066/EY). CONCLUSION: The visual prognosis in most cases of punctate inner choroidopathy is very good. The incidence rate of new CNV and recurrent CNV was 0.02/EY and 0.04/EY, respectively.

Original languageEnglish (US)
Pages (from-to)1666-1674
Number of pages9
JournalRetina
Volume34
Issue number8
DOIs
StatePublished - Aug 2014

Fingerprint

Incidence
Choroidal Neovascularization
Confidence Intervals
Vision Disorders
Visual Acuity
Cohort Studies
Immunomodulation
Retrospective Studies
Demography
Outcome Assessment (Health Care)
Recurrence
Drug Therapy

Keywords

  • Choroidal neovascularization
  • Intravitreal anti-VEGF
  • Punctate inner choroidopathy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Leung, T. G., Moradi, A., Liu, D., Nguyen, Q. D., Dunn, J. P., Burkholder, B., ... Thorne, J. E. (2014). Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. Retina, 34(8), 1666-1674. https://doi.org/10.1097/IAE.0000000000000125

Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. / Leung, Theresa G.; Moradi, Ahmadreza; Liu, Dianna; Nguyen, Quan D.; Dunn, James P.; Burkholder, Bryn; Butler, Nicholas J.; Ostheimer, Trucian; Thorne, Jennifer E.

In: Retina, Vol. 34, No. 8, 08.2014, p. 1666-1674.

Research output: Contribution to journalArticle

Leung, TG, Moradi, A, Liu, D, Nguyen, QD, Dunn, JP, Burkholder, B, Butler, NJ, Ostheimer, T & Thorne, JE 2014, 'Clinical features and incidence rate of ocular complications in punctate inner choroidopathy', Retina, vol. 34, no. 8, pp. 1666-1674. https://doi.org/10.1097/IAE.0000000000000125
Leung TG, Moradi A, Liu D, Nguyen QD, Dunn JP, Burkholder B et al. Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. Retina. 2014 Aug;34(8):1666-1674. https://doi.org/10.1097/IAE.0000000000000125
Leung, Theresa G. ; Moradi, Ahmadreza ; Liu, Dianna ; Nguyen, Quan D. ; Dunn, James P. ; Burkholder, Bryn ; Butler, Nicholas J. ; Ostheimer, Trucian ; Thorne, Jennifer E. / Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. In: Retina. 2014 ; Vol. 34, No. 8. pp. 1666-1674.
@article{51651c9fa6f44fb8bfa770212b78fd30,
title = "Clinical features and incidence rate of ocular complications in punctate inner choroidopathy",
abstract = "PURPOSE: To study the clinical features and incidence rate of ocular complications in patients with punctate inner choroidopathy. METHODS: This is a retrospective cohort study conducted in a single-center academic practice setting. Patients diagnosed with punctate inner choroidopathy at the Wilmer Eye Institute, Johns Hopkins University from 1984 to 2012 were identified. Demographics and clinical features including the presence of choroidal neovascularization (CNV) and structural complications were collected. Main outcome measures, including visual impairment and incidence rate of ocular complications, were analyzed. RESULTS: Thirty-one patients (59 eyes) were included in the study. Follow-up data were available for 24 patients (47 eyes) with a mean follow-up time of 3.4 years (range, 2 months to 8.7 years). In the affected eyes with follow-up, the incidence rate of visual impairment to 20/50 or worse was 0.06 per eye-year (EY) (95{\%} confidence interval, 0.022/EY-0.114/EY). The incidence rate of visual loss to 20/200 or worse was 0.006/EY (95{\%} confidence interval, 0.0001/EY-0.034/EY). Thirty-six eyes (77{\%}) had an ultimate visual acuity of 20/40 or better. All of the 13 patients with more than ≥3 years of follow-up had a visual acuity of ≥20/40 in at least 1 eye at 3 years after presentation. Two thirds of the follow-up patients (67{\%}) on immunomodulatory drug therapy did not have new or recurrent CNV. However, this was not a statistically significant difference. Three eyes with follow-up had recurrence of CNV for an incidence rate of 0.04/EY (95{\%} confidence interval, 0.008/EY-0.12/EY). Two eyes developed new CNV during follow-up for an incidence rate of 0.02/EY (95{\%} confidence interval, 0.002/EY-0.066/EY). CONCLUSION: The visual prognosis in most cases of punctate inner choroidopathy is very good. The incidence rate of new CNV and recurrent CNV was 0.02/EY and 0.04/EY, respectively.",
keywords = "Choroidal neovascularization, Intravitreal anti-VEGF, Punctate inner choroidopathy",
author = "Leung, {Theresa G.} and Ahmadreza Moradi and Dianna Liu and Nguyen, {Quan D.} and Dunn, {James P.} and Bryn Burkholder and Butler, {Nicholas J.} and Trucian Ostheimer and Thorne, {Jennifer E.}",
year = "2014",
month = "8",
doi = "10.1097/IAE.0000000000000125",
language = "English (US)",
volume = "34",
pages = "1666--1674",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Clinical features and incidence rate of ocular complications in punctate inner choroidopathy

AU - Leung, Theresa G.

AU - Moradi, Ahmadreza

AU - Liu, Dianna

AU - Nguyen, Quan D.

AU - Dunn, James P.

AU - Burkholder, Bryn

AU - Butler, Nicholas J.

AU - Ostheimer, Trucian

AU - Thorne, Jennifer E.

PY - 2014/8

Y1 - 2014/8

N2 - PURPOSE: To study the clinical features and incidence rate of ocular complications in patients with punctate inner choroidopathy. METHODS: This is a retrospective cohort study conducted in a single-center academic practice setting. Patients diagnosed with punctate inner choroidopathy at the Wilmer Eye Institute, Johns Hopkins University from 1984 to 2012 were identified. Demographics and clinical features including the presence of choroidal neovascularization (CNV) and structural complications were collected. Main outcome measures, including visual impairment and incidence rate of ocular complications, were analyzed. RESULTS: Thirty-one patients (59 eyes) were included in the study. Follow-up data were available for 24 patients (47 eyes) with a mean follow-up time of 3.4 years (range, 2 months to 8.7 years). In the affected eyes with follow-up, the incidence rate of visual impairment to 20/50 or worse was 0.06 per eye-year (EY) (95% confidence interval, 0.022/EY-0.114/EY). The incidence rate of visual loss to 20/200 or worse was 0.006/EY (95% confidence interval, 0.0001/EY-0.034/EY). Thirty-six eyes (77%) had an ultimate visual acuity of 20/40 or better. All of the 13 patients with more than ≥3 years of follow-up had a visual acuity of ≥20/40 in at least 1 eye at 3 years after presentation. Two thirds of the follow-up patients (67%) on immunomodulatory drug therapy did not have new or recurrent CNV. However, this was not a statistically significant difference. Three eyes with follow-up had recurrence of CNV for an incidence rate of 0.04/EY (95% confidence interval, 0.008/EY-0.12/EY). Two eyes developed new CNV during follow-up for an incidence rate of 0.02/EY (95% confidence interval, 0.002/EY-0.066/EY). CONCLUSION: The visual prognosis in most cases of punctate inner choroidopathy is very good. The incidence rate of new CNV and recurrent CNV was 0.02/EY and 0.04/EY, respectively.

AB - PURPOSE: To study the clinical features and incidence rate of ocular complications in patients with punctate inner choroidopathy. METHODS: This is a retrospective cohort study conducted in a single-center academic practice setting. Patients diagnosed with punctate inner choroidopathy at the Wilmer Eye Institute, Johns Hopkins University from 1984 to 2012 were identified. Demographics and clinical features including the presence of choroidal neovascularization (CNV) and structural complications were collected. Main outcome measures, including visual impairment and incidence rate of ocular complications, were analyzed. RESULTS: Thirty-one patients (59 eyes) were included in the study. Follow-up data were available for 24 patients (47 eyes) with a mean follow-up time of 3.4 years (range, 2 months to 8.7 years). In the affected eyes with follow-up, the incidence rate of visual impairment to 20/50 or worse was 0.06 per eye-year (EY) (95% confidence interval, 0.022/EY-0.114/EY). The incidence rate of visual loss to 20/200 or worse was 0.006/EY (95% confidence interval, 0.0001/EY-0.034/EY). Thirty-six eyes (77%) had an ultimate visual acuity of 20/40 or better. All of the 13 patients with more than ≥3 years of follow-up had a visual acuity of ≥20/40 in at least 1 eye at 3 years after presentation. Two thirds of the follow-up patients (67%) on immunomodulatory drug therapy did not have new or recurrent CNV. However, this was not a statistically significant difference. Three eyes with follow-up had recurrence of CNV for an incidence rate of 0.04/EY (95% confidence interval, 0.008/EY-0.12/EY). Two eyes developed new CNV during follow-up for an incidence rate of 0.02/EY (95% confidence interval, 0.002/EY-0.066/EY). CONCLUSION: The visual prognosis in most cases of punctate inner choroidopathy is very good. The incidence rate of new CNV and recurrent CNV was 0.02/EY and 0.04/EY, respectively.

KW - Choroidal neovascularization

KW - Intravitreal anti-VEGF

KW - Punctate inner choroidopathy

UR - http://www.scopus.com/inward/record.url?scp=84905087148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905087148&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000125

DO - 10.1097/IAE.0000000000000125

M3 - Article

C2 - 24743642

AN - SCOPUS:84905087148

VL - 34

SP - 1666

EP - 1674

JO - Retina

JF - Retina

SN - 0275-004X

IS - 8

ER -